Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Natco Pharma today declared that it has gotten a last endorsement for its first supplemental condensed new medication application (ANDA) item from US Food and Drug Administration (USFDA) documented from its new medication plan office in JNPC SEZ, Ramky Pharma City, Visakhapatnam (Andhra Pradesh).
ANDA, submitted as ‘earlier endorsement supplement’, accommodates NATCO’s Visakhapatnam office as a substitute site for the assembling of the affirmed sedate item for US advertise.
Not long ago, the organization had gotten a conclusion of assessment with a foundation examination report (EIR) from US Food and Drug Administration (FDA) for the pre-endorsement review led at its medication details office in Kothur town (Telangana) during the period from March 2 to March 6, 2020.